Tatsuro Fukuhara

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya et al. · The Lancet Oncology · 2019 · 626 citations

Interim Analysis, Oncology, Bevacizumab Versus Erlotinib +8

Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

Akira Inoue, Takuji Suzuki, Tatsuro Fukuhara et al. · Journal of Clinical Oncology · 2006 · 503 citations · Full text

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

Yukio Hosomi, Satoshi Morita, Shunichi Sugawara et al. · Journal of Clinical Oncology · 2019 · 473 citations

PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth

Mami Morita, Taku Sato, Miyuki Nomura et al. · Cancer Cell · 2018 · 173 citations · Full text

Tumor Biology, Cell Regulation, Medicine +8

Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).

Atsushi Nakamura, Akira Inoue, Satoshi Morita et al. · Journal of Clinical Oncology · 2018 · 112 citations

Cancer Management, Gefitinib Monotherapy, Pathology +19